GLPwatch
Papers (10382)
Page 113 of 174, ranked by citation count.
- Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.
- Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials.
- [The pharmacological treatment of obesity: past, present and future].
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A.
- [Effects of Exenatide-4 on proliferation, migration and osteogenic differentiation of human periodontal ligament stem cells].
- Semaglutide attenuates Alzheimer's disease model progression by targeting microglial NLRP3 inflammasome-mediated neuroinflammation and ferroptosis.
- Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin.
- Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial.
- Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
- Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database.
- Comparison of the Effectiveness of Liraglutide vs Semaglutide in a Veteran Population.
- Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Cataract Development.
- Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?
- Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet.
- Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia.
- Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study
- The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression.
- Influence and significance of intervening diabetes microRNA expression profile of NOD mice with exendin-4.
- GLP-1 receptor agonists for the treatment of alcohol use disorder.
- Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice.
- The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.
- GLP-1/GIP dual agonist tirzepatide alleviates mice model of Parkinson's disease by promoting mitochondrial homeostasis.
- iGlarLixi for type 2 diabetes: a systematic review and meta-analysis.
- A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects.
- Online Information About Side Effects and Safety Concerns of Semaglutide: Mixed Methods Study of YouTube Videos.
- iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trial.
- Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicity.
- Analysing the effects of National Centralised Drug Procurement and Price Negotiation Policies on novel hypoglycaemic drug usage and costs in Shanghai, China: an interrupted time series analysis.
- Effects of weight-loss interventions on bone health in people living with obesity.
- Qualitative and Quantitative Analyses of Noninvasive Diagnosis of Insulinoma Using [18F]FB(ePEG12)12-Exendin-4 PET/CT.
- Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption.
- Activation of the HPA Axis Does Not Explain Nonresponsiveness to GLP-1R Agonist Treatment in Individuals With Type 2 Diabetes.
- The association between previous use of anti-obesity medication and semaglutide weight loss outcomes.
- Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic.
- Exendin-4 Attenuates Hepatic Steatosis by Promoting the Autophagy-Lysosomal Pathway.
- Glucagon-like peptide-1 analogues exenatide and liraglutide exert inhibitory effect on the early phase of liver regeneration after partial hepatectomy in rats.
- Inhibition of notch signalling and mesangial expansion by combined glucagon like peptide-1 agonist and crocin therapy in animal model of diabetic nephropathy.
- The G Protein-First Mechanism for Activation of the Class B Glucagon-like Peptide 1 Receptor Coupled to N-Terminal Domain-Mediated Conformational Progression.
- Distinct roles of the extracellular surface residues of glucagon-like peptide-1 receptor in β-arrestin 1/2 signaling.
- Impact of Insulin Sensitivity and β-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy.
- Impact of GLP-1 Receptor Agonist Use in Patients With Steatotic Liver Disease and Type 2 Diabetes: A Retrospective Cohort Study.
- The Hypoglycemic and Hypocholesterolemic Activity of <i>Dioscorea deltoidea</i>, <i>Tribulus terrestris</i> and <i>Panax japonicus</i> Cell Culture Biomass in Rats with High-Fat Diet-Induced Obesity.
- Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives.
- <i>KCNQ1</i> variant rs163184 is a potential biomarker of glycemic response to exenatide.
- Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial.
- Real world effectiveness of oral semaglutide: Focus on patients with type 2 diabetes older than 75 years.
- Tirzepatide, a novel, dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist for the ongoing diabesity epidemic: the dawn of a new era?
- Lack of Benefit for Liraglutide in Heart Failure.
- Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows.
- Glucagon‑like peptide‑1 analogue exendin‑4 modulates serotonin transporter expression in intestinal epithelial cells.
- Insulin tolerance test predicts non response vs. sustained efficacy of Liraglutide on glycemic control in type 2 diabetes patients: A prospective real-world setting study.
- FRAP analysis of peptide diffusion in extracellular matrix mimetic hydrogels as an in vitro model for subcutaneous injection.
- Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus.
- Diabetes drugs activate neuroprotective pathways in models of neonatal hypoxic-ischemic encephalopathy.
- Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering Medications in Treating Type 2 Diabetes: A Comprehensive Systematic Review and Meta-analysis.
- Sex-specific effects of metformin and liraglutide on renal pathology and expression of connexin 45 and pannexin 1 following long-term high-fat high-sugar diet.
- Cutaneous hypersensitivity reaction to dulaglutide: A case report of an allergic reaction.
- [A 45-fold liraglutide overdose did not cause hypoglycaemia].